ATE272070T1 - Lösliche monovalente und multivalente mhc klasse ii fusionsproteine und deren verwendungen - Google Patents

Lösliche monovalente und multivalente mhc klasse ii fusionsproteine und deren verwendungen

Info

Publication number
ATE272070T1
ATE272070T1 AT97938386T AT97938386T ATE272070T1 AT E272070 T1 ATE272070 T1 AT E272070T1 AT 97938386 T AT97938386 T AT 97938386T AT 97938386 T AT97938386 T AT 97938386T AT E272070 T1 ATE272070 T1 AT E272070T1
Authority
AT
Austria
Prior art keywords
fusion proteins
mhc class
soluble monovalent
multivalent mhc
multivalent
Prior art date
Application number
AT97938386T
Other languages
English (en)
Inventor
Kai W Wucherpfennig
Jack L Strominger
Original Assignee
Harvard College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Harvard College filed Critical Harvard College
Application granted granted Critical
Publication of ATE272070T1 publication Critical patent/ATE272070T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT97938386T 1996-08-16 1997-08-15 Lösliche monovalente und multivalente mhc klasse ii fusionsproteine und deren verwendungen ATE272070T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2407796P 1996-08-16 1996-08-16
PCT/US1997/014503 WO1998006749A2 (en) 1996-08-16 1997-08-15 Soluble monovalent and multivalent mhc class ii fusion proteins, and uses therefor

Publications (1)

Publication Number Publication Date
ATE272070T1 true ATE272070T1 (de) 2004-08-15

Family

ID=21818743

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97938386T ATE272070T1 (de) 1996-08-16 1997-08-15 Lösliche monovalente und multivalente mhc klasse ii fusionsproteine und deren verwendungen

Country Status (11)

Country Link
EP (1) EP0935607B1 (de)
JP (1) JP2000516470A (de)
AT (1) ATE272070T1 (de)
AU (1) AU730457B2 (de)
CA (1) CA2263195A1 (de)
DE (1) DE69730038T2 (de)
DK (1) DK0935607T3 (de)
ES (1) ES2221065T3 (de)
NZ (1) NZ333915A (de)
PT (1) PT935607E (de)
WO (1) WO1998006749A2 (de)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0889964A1 (de) 1996-03-28 1999-01-13 The Johns Hopkins University Lösliche divalente und multivalente heterodimäre proteinanalogen
US6458354B1 (en) 1996-03-28 2002-10-01 The Johns Hopkins University Molecular complexes which modify immune responses
US6268411B1 (en) 1997-09-11 2001-07-31 The Johns Hopkins University Use of multivalent chimeric peptide-loaded, MHC/ig molecules to detect, activate or suppress antigen-specific T cell-dependent immune responses
WO1999042597A1 (en) * 1998-02-19 1999-08-26 President And Fellows Of Harvard College Monovalent, multivalent, and multimeric mhc binding domain fusion proteins and conjugates, and uses therefor
FR2778669B1 (fr) * 1998-05-14 2002-06-14 Centre Nat Rech Scient Procede d'expression d'un complexe forme d'au moins un produit du complexe majeur d'histocompatibilite et d'un peptide chez un phage, phages et complexes ainsi obtenus et leurs applications
BR9910253A (pt) * 1998-05-19 2002-09-17 Avidex Ltd Receptor de célula t solúvel
FR2796953B1 (fr) * 1999-07-29 2003-10-10 Centre Nat Rech Scient Proteines recombinantes, et complexes moleculaires derives de ces proteines, analogues a des molecules impliquees dans les reponses immunitaires
US7521202B2 (en) 1999-12-17 2009-04-21 The Board Of Regents Of The University Of Oklahoma Method and apparatus for the production of soluble MHC antigens and uses thereof
JP2004536554A (ja) 2000-10-10 2004-12-09 ザ ボード オブ リージェンツ オブ ザ ユニヴァーシティー オブ オクラホマ Ｍｈｃ陽性細胞からの比較リガンドマッピング
US20070026433A1 (en) 2001-03-09 2007-02-01 Hildebrand William H Epitope testing using soluble HLA
EP1353950A2 (de) * 2000-12-18 2003-10-22 William H. Hildebrand Verfahren und vorrichtung zur herstellung von antigene und deren verwendungen
US7094555B2 (en) 2001-04-05 2006-08-22 Benaroya Research Institute At Virginia Mason Methods of MHC class II epitope mapping, detection of autoimmune T cells and antigens, and autoimmune treatment
GB2392158B (en) * 2002-08-21 2005-02-16 Proimmune Ltd Chimeric MHC protein and oligomer thereof
ES2559763T3 (es) * 2002-09-10 2016-02-15 Affimed Gmbh Anticuerpo humano específico de CD3 con propiedades inmunosupresoras
EP2204190A1 (de) 2003-07-15 2010-07-07 Chugai Seiyaku Kabushiki Kaisha IgM-Produktion durch umgewandelte Zellen und Verfahren zur Quantifizierung der IgM-Produktion
JP4762717B2 (ja) 2003-10-09 2011-08-31 中外製薬株式会社 ＩｇＭ高濃度安定化溶液
GB2409456B (en) * 2003-10-30 2006-01-04 Proimmune Ltd Oligomeric receptor ligand pair member complexes
EP2155782A2 (de) 2007-03-26 2010-02-24 Dako Denmark A/S Mhc-peptid-komplexe und anwendungen davon bei infektionskrankheiten
EP2167537A2 (de) 2007-07-03 2010-03-31 Dako Denmark A/S Zusammengestellte verfahren für die analyse und sortierung von proben
US10611818B2 (en) 2007-09-27 2020-04-07 Agilent Technologies, Inc. MHC multimers in tuberculosis diagnostics, vaccine and therapeutics
DK2254592T3 (da) 2008-02-28 2019-09-09 Dako Denmark As MHC-multimerer til Borrelia-diagnostik og sygdom
WO2010009735A2 (en) 2008-07-23 2010-01-28 Dako Denmark A/S Combinatorial analysis and repair
GB0817244D0 (en) 2008-09-20 2008-10-29 Univ Cardiff Use of a protein kinase inhibitor to detect immune cells, such as T cells
US11992518B2 (en) 2008-10-02 2024-05-28 Agilent Technologies, Inc. Molecular vaccines for infectious disease
WO2010037402A1 (en) 2008-10-02 2010-04-08 Dako Denmark A/S Molecular vaccines for infectious disease
GB201002730D0 (en) * 2010-02-18 2010-04-07 Uni I Oslo Product
US9511151B2 (en) 2010-11-12 2016-12-06 Uti Limited Partnership Compositions and methods for the prevention and treatment of cancer
CA2860678A1 (en) * 2012-01-06 2013-07-11 Oregon Health & Science University Partial mhc constructs and methods of use
JP6362543B2 (ja) 2012-02-23 2018-07-25 ジュノ セラピューティクス ゲーエムベーハー 細胞および他の複雑な生物学的材料のクロマトグラフィーによる単離
US10988516B2 (en) 2012-03-26 2021-04-27 Uti Limited Partnership Methods and compositions for treating inflammation
US9603948B2 (en) 2012-10-11 2017-03-28 Uti Limited Partnership Methods and compositions for treating multiple sclerosis and related disorders
GB201309469D0 (en) 2013-05-28 2013-07-10 Imcyse Sa Detection of CD4+ T lymphocytes
EP3052526A4 (de) 2013-10-03 2017-04-19 Oregon Health & Science University Rekombinante polypeptide mit mhc-klasse-ii-1-domänen
JP2017500285A (ja) 2013-11-04 2017-01-05 ユーティーアイ リミテッド パートナーシップ 持続的免疫療法のための方法および組成物
WO2015148960A1 (en) 2014-03-28 2015-10-01 The Board Of Regents Of The University Of Oklahoma Compositions comprising soluble hla/m. tuberculosis-specific ligand complexes and methods of production and use thereof
SG10201913680PA (en) 2014-05-29 2020-03-30 Macrogenics Inc Tri-specific binding molecules that specifically bind to multiple cancer antigens and methods of use thereof
WO2015188839A2 (en) 2014-06-13 2015-12-17 Immudex Aps General detection and isolation of specific cells by binding of labeled molecules
SG10201913957PA (en) 2015-05-06 2020-03-30 Uti Lp Nanoparticle compositions for sustained therapy
CN108136010A (zh) 2015-10-08 2018-06-08 宏观基因有限公司 用于治疗癌症的联合疗法
HK1258932A1 (zh) 2015-10-22 2019-11-22 Juno Therapeutics Gmbh 用於转导的方法、反应剂盒、反应剂和设备
CN108474791B (zh) 2015-10-22 2022-07-08 朱诺治疗学有限公司 培养细胞的方法及用于该方法的试剂盒和设备
KR20260011774A (ko) * 2016-11-09 2026-01-23 유티아이 리미티드 파트너쉽 재조합 pMHC II형 분자
MA49288A (fr) 2017-04-27 2020-03-04 Juno Therapeutics Gmbh Reactifs particulaires oligomères et leurs méthodes d'utilisation
JP7436372B2 (ja) 2017-11-29 2024-02-21 ユーティアイ・リミテッド・パートナーシップ 自己免疫性疾患を治療する方法
WO2020018715A1 (en) * 2018-07-17 2020-01-23 Massachusetts Institute Of Technology Soluble multimeric immunoglobulin-scaffold based fusion proteins and uses thereof
EP3874024A1 (de) 2018-10-31 2021-09-08 Juno Therapeutics GmbH Verfahren zur selektion und stimulation von zellen und vorrichtung dafür
WO2020127222A2 (en) 2018-12-17 2020-06-25 Immudex Aps Panel comprising borrelia mhc multimers
GB201909509D0 (en) * 2019-07-02 2019-08-14 Immunocore Ltd Peptide-MHC complexes
RU2753282C2 (ru) * 2019-09-19 2021-08-12 Закрытое Акционерное Общество "Биокад" ИММУНОЦИТОКИН, ВКЛЮЧАЮЩИЙ ГЕТЕРОДИМЕРНЫЙ БЕЛКОВЫЙ КОМПЛЕКС НА ОСНОВЕ IL-15/IL-15Rα, И ЕГО ПРИМЕНЕНИЕ
CN112816595A (zh) * 2021-01-06 2021-05-18 海默斯（重庆）医学生物技术有限公司 一种重组角蛋白液体制剂及其纯度检测方法
WO2022216974A1 (en) * 2021-04-07 2022-10-13 Repertoire Immune Medicines, Inc. Peptide-mhc-immunoglobulin multimers and methods of use thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993010220A1 (en) * 1991-11-19 1993-05-27 Anergen, Inc. Soluble mhc molecules and their uses
EP0997477B1 (de) * 1994-07-29 2006-03-15 Sunol Molecular Corporation MHC-Komplexe und ihre Verwendung

Also Published As

Publication number Publication date
CA2263195A1 (en) 1998-02-19
AU730457B2 (en) 2001-03-08
WO1998006749A3 (en) 1998-06-11
NZ333915A (en) 2000-11-24
WO1998006749A2 (en) 1998-02-19
DE69730038D1 (de) 2004-09-02
ES2221065T3 (es) 2004-12-16
DE69730038T2 (de) 2004-11-25
JP2000516470A (ja) 2000-12-12
EP0935607B1 (de) 2004-07-28
DK0935607T3 (da) 2004-12-06
AU4072397A (en) 1998-03-06
EP0935607A2 (de) 1999-08-18
PT935607E (pt) 2004-12-31

Similar Documents

Publication Publication Date Title
DE69730038D1 (de) Lösliche monovalente und multivalente mhc klasse ii fusionsproteine und deren verwendungen
CY1107706T1 (el) Πεπτιδια ανταγωνιστες καρκινοεμβρυονικου αντιγονου (cea)
ATE328068T1 (de) Papillomavirus vakzine
TR199801722T2 (xx) Peptit imm�nojenler.
DK1053256T3 (da) Antistoffer mod Dødsreceptor 4 (DR4) og anvendelser deraf
CY1108610T1 (el) Πεπτιδια της il-2 και παραγωγα αυτων και χρηση αυτων ως θεραπευτικοι παραγοντες
DE69824013D1 (de) Impfstoff gegen hpv
DK0975333T3 (da) Alginatgel med langvarig frigörelse
ATE229978T1 (de) Helicobacter proteine und impstoffe
ATE339507T1 (de) Erythropoietin-analog-menschliches serum-albumin fusionsprotein
DK0960127T3 (da) Isoleret dimert fibroblastaktiverende protein-alfa og anvendelser deraf
CY1105963T1 (el) Συνθεσεις καψομepιδιακου εμβολιου του ιου του θηλωματος και μεθοδοι χρησης
DE69524389D1 (de) 6-substituierte mycophenolsäurederivate mit immun suppressiver wirkung
DK0538300T3 (da) O-Glycosyleret IFN-alfa
ATE211467T1 (de) 4-amino-derivate der mycophenolsäure mit immun suppressiver wirkung
DE69930630D1 (de) B2microglobulin fusionsproteine und varianten mit hoher affinität
DE69838986D1 (de) Polypeptide, deren herstellung und verwendung
ATE190659T1 (de) Rekombinante immuntoxine
DE69127821D1 (de) Herstellung von siliciumnitrid mit verdichtungshilfsmittel, und resultate
TR200001102T2 (tr) İkameli tetrahidropirimidinen türevleri, üretimleri ve kullanımları.
DK1040191T3 (da) RANTES-mutanter og terapeutiske anvendelser heraf
TR199800575T1 (en) Kemokin �-8'in k�sa formlar�.
ATE341339T1 (de) Zusammensetzungen von rekombinanten papillomavirus vakzinen
DE3751834D1 (de) Selbstantigen der primären lebercirrhose
DE59709066D1 (de) Mittel zur dauerhaften Verformung von menschlichen Haaren

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0935607

Country of ref document: EP

REN Ceased due to non-payment of the annual fee